Overview of Gene Therapy Clinical Studies for BAG3-DCM
Date: April 15, 2026
Time: 6:00pm EDT
Rocket Pharmaceuticals will provide high-level overviews of clinical trials and adeno-associated virus (AAV) gene therapy for BAG3 cardiomyopathy. Dr. Kasetty will also present more detailed information on RP-A701 BAG3 Gene Therapy.
The RP-A701 BAG3 Gene Therapy is an investigational gene therapy being developed specifically for people with dilated cardiomyopathy caused by a BAG3 mutation. The investigational therapy is designed to deliver a working copy of the BAG3 gene to heart muscle cells, with the goal of helping those cells produce the BAG3 protein at more typical levels. By addressing the underlying genetic cause of the disease, this investigational approach is intended to support healthier heart cell function and slow or stabilize disease progression.
Presenter: Mayur Kasetty, MD, Associate Vice President, AAV Global Program Head
